<SUBMISSION>
<ACCESSION-NUMBER>0000950131-00-006979
<TYPE>DFAN14A
<PUBLIC-DOCUMENT-COUNT>4
<FILING-DATE>20001229
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>STAAR SURGICAL COMPANY
<CIK>0000718937
<ASSIGNED-SIC>3851
<IRS-NUMBER>953797439
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>0101
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>DFAN14A
<ACT>34
<FILE-NUMBER>000-11634
<FILM-NUMBER>799456
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1911 WALKER AVE
<CITY>MONROVIA
<STATE>CA
<ZIP>91016
<PHONE>8183037902
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1911 WALKER AVE
<CITY>MONROVIA
<STATE>CA
<ZIP>91016
</MAIL-ADDRESS>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>NOVASTAAR INVESTMENTS LLC
<CIK>0001130952
<ASSIGNED-SIC>
<IRS-NUMBER>760660300
<STATE-OF-INCORPORATION>TX
<FISCAL-YEAR-END>1221
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>DFAN14A
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6750 W LOOP SOUTH
<STREET2>SUITE 500
<CITY>BELLAIRE
<STATE>TX
<ZIP>77401
<PHONE>713628561
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6750 W LOOP SOUTH
<STREET2>SUITE 500
<CITY>BELLAIRE
<STATE>TX
<ZIP>77401
</MAIL-ADDRESS>
</FILED-BY>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>0001.txt
<DESCRIPTION>SCHEDULE 14A
<TEXT>

<PAGE>

                            SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.        )

Filed by the Registrant [  ]
Filed by a Party other than the Registrant [X]

Check the appropriate box:

[ ]    Preliminary Proxy Statement
[ ]    Confidential, for Use of the Commission Only (as permitted by Rule
       14a-6(e)(2))
[ ]    Definitive Proxy Statement
[ ]    Definitive Additional Materials
[X]    Soliciting Material Pursuant to 240.14a-12

                             Staar Surgical Company
                (Name of Registrant as Specified In Its Charter)

                Novastaar Investments, LLC and Lamar F. Laster, Jr.
     (Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X]    No fee required.
[ ]    Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

       1)      Title of each class of securities to which transaction applies:
               .......................................................
       2)      Aggregate number of securities to which transaction applies:
               .......................................................
       3)      Per unit price or other underlying value of transaction computed
               pursuant to Ex-change Act Rule 0-11 (Set forth the amount on
               which the filing fee is calculated and state how it was
               determined):
               .......................................................
       4)      Proposed maximum aggregate value of transaction:
               .......................................................
       5)      Total fee paid:
               ......................................................

[ ]    Fee paid previously with preliminary materials.

[ ]    Check box if any part of the fee is offset as provided by the Exchange
       Act Rule 0_11(a)(2) and identify the filing for which the offsetting fee
       was paid previously. Identify the previ-ous filing by registration
       statement number, or the Form or Schedule and the date of its filing.

        1)      Amount Previously Paid:
                .......................................................
        2)      Form, Schedule or Registration Statement No.:
                .......................................................
        3)      Filing Party:
                .......................................................
        4)      Date Filed:
                .......................................................

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>0002.txt
<DESCRIPTION>PRESS RELEASE DATED 12/18/2000
<TEXT>

<PAGE>
                                                                    Exhibit 99.1

To:     Bill Roberts
E-Mail: ctsroberts@aol.com       Ph. #: 937-434-2700
        ------------------

                         Date:  December 18, 2000

Contact:  Mr. LaMar F. Laster, Jr.
          NovaStaar Investments, LLC
          Phone: (713) 662-8561
          Fax:  (713) 662-8504

STAAR SURGICAL COMPANY SUED BY NOVASTAAR INVESTMENTS, LLC AND LAMAR F. LASTER

Houston, Texas - December 18, 2000 - LaMar F. Laster and NovaStaar Investments,
LLC filed a complaint against Staar Surgical Company (NASDAQ:STAA) in the Court
of Chancery of the State of Delaware demanding to inspect, and make copies and
extras of, certain documents of Staar.

The complaint is being filed by Mr. Laster and NovaStaar Investments, both
shareholders of Staar, in response to the refusal of Staar to provide certain
documents to NovaStaar Investments as provided for under Delaware General
Corporation Law.

The documents requested by NovaStaar Investments include the following of Staar:
(1) stock ledger, (2) list of stockholders, (3) minute books, and (4) minutes
and consents representing all proceedings by shareholders, directors or
committees not contained in the minute books.

Additionally, NovaStaar Investments has requested all other books and records of
Staar relating to:

1)  approximately $6,000,000 in loans by Staar to certain of its officers and
    directors;

2)  services provided by and fees paid by Staar to Pollet & Richardson, of which
    Andrew F. Pollet, a Director and acting Chief Executive Officer of Staar, is
    a partner;

3)  services provided by and fees paid to Iotech, Inc., a company controlled by
    John R. Wolf, a Director of Staar and its former Chief Executive Officer;

4)  Staar's plan of restructuring which provided approximately $24,000,000 of
    write-offs and charges;

5)  recent management changes, including the termination of employment of John
    R. Wolf, Vladimir Feingold, William C. Huddleston, Michael Lloyd, Thomas
    Chambers, and Richard Leza;

6)  defaulted loans and other credit arrangements with Wells Fargo Bank and
    other lenders;

7)  Staar's deteriorating current ratio and decreasing sales and profits;

8)  litigation and arbitration proceeding involving Canon-Staar, Inc. and Canon,
    Inc.,
<PAGE>

    Japan;

9)  the recent promotion of John Santos to the office of President and Chief
    Executive Officer, and subsequent demotion; and

10) recent Board of Directors activity including the termination of Andrew F.
    Pollet as Chairman, President and Chief Executive Officer and the subsequent
    cancellation of the same, and the appointment of Richard Priske, allegedly
    Andrew F. Pollet's brother-in-law, as a Director of Staar.

NovaStaar Investments, LLC is based in Houston, Texas.  NovaStaar Investments'
Chief Executive Officer and Chairman is LaMar F. Laster, the former Chairman and
Chief Operating Officer of Staar and one of Staar's founders.
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>0003.txt
<DESCRIPTION>PRESS RELEASE DATED 12/27/2000
<TEXT>

<PAGE>
                                                                    Exhibit 99.2

           Staar Surgical Company Fails to Disclose Potential Canon
                          Damages of over $70,000,000

Bellaire Texas, December 27, 2000, PR Newswire/--NovaStaar Investments, LLC
Chairman and CEO, LaMar F. Laster, Jr. offered the following information to
Staar Surgical Company (Nasdaq: STAA) Shareholders:

"Following our press release last week, dated December 21, 2000, wherein we
alluded to what we believe to be a failure by Staar management to disclose
material information regarding the Canon Companies, Japan, we anticipated that
Staar management would voluntarily comply with SEC and Nasdaq requirements to
fully disclose.  Given that such disclosures do not appear to be forthcoming, we
offer the following in an effort to level the playing field for all shareholders
by sharing pertinent information.

According to documents filed by the Canon Companies, Japan and Staar Surgical
Company in California Superior Court and in a pending International Arbitration
proceeding, Canon is alleging the following and other claims:

     1.  That Staar Surgical Company willfully breached the Joint Venture
         agreement with the Canon Companies by entering into licensing
         agreements with Bausch and Lomb/Chiron, and Allergan, Inc. contrary to
         a pre-existing exclusive license to the Canon companies for the
         territory of Japan.

     2.  That Staar Surgical Company willfully withheld proprietary raw
         materials necessary for the production of Canon-Staar (the Joint
         Venture Company) lenses, which inhibited production and sales of that
         company's products in the territory of Japan.

     3.  That Staar Surgical Company willfully withheld access to proprietary
         new Staar products including the Staar ICL and Glaucoma Wick, in
         violation of the terms of the Joint Venture Agreement.

     4.  That John R. Wolf, former President and CEO of Staar, willfully entered
         into secret contracts with Bausch and Lomb/Chiron, and Allergan, Inc.
         as President of Canon-Staar, without the approval of the Board of
         Canon-Staar.

The Arbitration documents also contain disclosures that Mr. Wolf's latest
contract renewal with Staar allowed for the forgiveness of loans owed by him to
the company totaling more than $2.0 Million, and that Mr. Wolf's company IOTECH,
Inc. was paid over $1.2 Million upon his termination".

Additional information contained in the Arbitration documents include the fact
that the Canon Companies are seeking damages of 8.0 billion Japanese Yen,
currently equivalent to over $70.0 million."
<PAGE>

About NovaStaar

NovaStaar Investments, LLC is a private company specifically formed in 1999 to
make a friendly tender offer for the control of Staar Surgical Company.
NovaStaar's 1999 offer of $15 per share was rebuffed by Staar.  Beginning in
early 2000, NovaStaar principals were repeatedly approached by past and current
shareholders, directors, management, and employees of Staar.  These concerned
parties wanted to determine NovaStaar's interest in helping to pursue the best
long term alternatives for all Staar Shareholders.  NovaStaar is now attempting
to carry out normal due diligence through its request for information to Staar
management before making a determination of its ultimate level of interest.


Contact:  Mr. LaMar F. Laster, Jr.
NovaStaar Investments, LLC
Phone: (713) 662-8561
Fax:  (713) 662-8504
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>0004.txt
<DESCRIPTION>PRESS RELEASE DATED 12/29/2000
<TEXT>

<PAGE>
                                                                    Exhibit 99.3

        Staar Surgical's New CEO Asked to Convene Special Shareholders
                     Meeting by NovaStaar Investments, LLC

Bellaire, Texas, December 29, 2000/PR Newswire/--NovaStaar Investments, LLC,
Chairman and CEO, LaMar F. Laster, Jr., requested that Mr. David Bailey, the
newly appointed President and CEO of Staar Surgical Company (Nasdaq: STAA), call
a special shareholders meeting as is allowed under Staar Surgical's current By-
Laws.

Laster stated, "We believe a special shareholders meeting is warranted, given
recent disclosures. These include:  apparent dissension at the board level,
alleged unauthorized forgiveness of major debts owed the company by officers and
directors, litigation claiming self dealing and conflicts of interest among
management and the board, and the alleged purposeful entanglement of the company
by management in major litigation with the Canon companies."

Continuing NovaStaar's Laster said, "We believe Mr. Bailey should want his
tenure at Staar to begin with a clear mandate from shareholders, with the
ability to move forward unencumbered by the old board, which is currently
besieged with litigation by both internal and external forces."

"We request that an alternate slate of directors, submitted by a committee of
shareholders, be nominated for consideration by all shareholders.  Only then
will the newly elected directors be viewed as truly independent.  The ultimate
authority, over how Staar Surgical is run, and who will run it in the future,
should rest in the hands of the shareholders."

About NovaStaar

NovaStaar Investments, LLC is a private company specifically formed in 1999 to
make a friendly tender offer for the control of Staar Surgical Company.
NovaStaar's 1999 offer of $15 per share was rebuffed by Staar.  Beginning in
early 2000, NovaStaar principals were repeatedly approached by past and current
shareholders, directors, management, and employees of Staar.  These concerned
parties wanted to determine our interest in helping to pursue the best long term
alternatives for all Staar Shareholders.  NovaStaar is now attempting to carry
out normal due diligence through its request for information to Staar management
before making a determination of its ultimate level of interest.


Contact:  Mr. LaMar F. Laster, Jr.
          NovaStaar Investments, LLC
          Phone:  (713) 662-8561
          Fax:    (713) 662-8504
</TEXT>
</DOCUMENT>
</SUBMISSION>
